 | | Vol. 13.13 – 8 April, 2022 |
| |
|
|
| Mediator 1 (MED1) phosphorylation increased during prostate cancer progression to the lethal phase, and pharmacological inhibition of cyclin-dependent kinase 9 decreased prostate tumor growth by decreasing MED1 phosphorylation and RNA polymerase II recycling.
[Nucleic Acids Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers defined mesenchymal and stem-like prostate cancer, traced its origin to therapy-induced lineage plasticity, and revealed its sensitivity to HER2/3 inhibition.
[Cell Reports] |
|
|
|
| Scientists investigated the expression of the protein tyrosine phosphatase receptor type F polypeptide interacting protein alpha 4 (PPFIA4) using public datasets and tumor specimens from prostate cancer cases by immunohistochemistry.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers observed that cell migration-inducing protein (CEMIP) upregulation facilitated ferroptosis resistance during ECM detachment by promoting cystine uptake in prostate cancer cells.
[Cancer Science] |
|
|
|
| Hypoxia increased androgen receptor expression and transcriptional activity in prostate cells in vitro.
[Molecular Cancer Research] |
|
|
|
| In primary prostate luminal epithelial cells, following inducible oncogenic Kras expression or Pten depletion, TMPRSS2-ERG suppressed oncogene-induced senescence, independent of TP53 induction and RB1 inhibition.
[Cancer Gene Therapy] |
|
|
|
| The authors indicated a relationship between synaptosome associated protein 25 (SNAP25) expression and prostate cancer, demonstrating that SNAP25 was a potential prognostic biomarker due to its vital role in immune infiltration.
[Cancer Cell International] |
|
|
|
| Investigators addressed the species specificity of growth hormone (GH)-GH receptor activity by investigating GH actions in prostate cancer cell lines derived from a mouse Pten deletion model.
[Endocrinology] |
|
|
|
| The prostatic epithelial cell RWPE-1 and prostate cancer cell DU145 were exposed to Fraxetin to detect the changes in cell viability using cell counting kit-8 assay.
[Bioengineered] |
|  |
|
|
|
| The evolution towards a routine, fully MRI-guided active surveillance pathway has to be preceded by ensuring quality programme assessment for MRI reading and by demonstrating its safety in prospective trials.
[Nature Reviews Urology] |
|
|
|
| Further study into the “Gut–Prostate Axis” would help in the discovery of new strategies for the prevention, screening, and treatment of prostate cancer.
[International Journal of Urology] |
|
|
|
|
| NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831 for the treatment of patients with advanced solid tumors.The trial expects to enroll adult patients with multiple tumor types, including pancreatic cancer, breast cancer and prostate cancer.
[NGM Biopharmaceuticals, Inc.] |
|
|
|
|
| June 15 – 18, 2022
San Francisco, California, United States |
|
|
|
|
|
| | Washington State University – Spokane, Washington, United States |
|
|
|
| | Helmholtz Munich – Neuherberg, Germany |
|
|
|
| | CRUK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | University of Southern Denmark – Odense M, Denmark |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
